

ASX RELEASE

2 July 2025

Cleansing Notice

Paradigm Biopharmaceuticals Ltd (ASX:PAR) (“**Paradigm**” or “**the Company**”), confirms on 1 July 2025, it completed the issue of 8,000,000 fully paid ordinary shares in the capital of the Company (**Shares**) pursuant to a Convertible Securities Agreement, previously announced on 1 July 2025.

The Company gives notice pursuant to section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**) that:

1. the Company issued the Shares without disclosure to investors under Part 6D.2 of the Corporations Act; and
2. as at the date of this notice, the Company has complied with:
 - a. the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - b. section 674 and section 674A of the Corporations Act; and
3. as at the date of this notice, there is no information that is “excluded information” (as defined in section 708A(7) of the Corporations Act) which is required to be disclosed by the Company in accordance with Section 708A(8) of the Corporations Act.

Authorised on behalf of the Board of Directors.

Paul Rennie
Managing Director
Paradigm Biopharmaceuticals Ltd.

-Ends